Lifeline Biotechnologies Inc (LLBO)

[Domains]

What we don't know vs. what we know

PENDING

PENDING - A current photo of iTbra in a real bra (a ready to sell product)
PENDING - Demonstration that we have an app ready to use via mobile
PENDING - Demonstration of the entire product life cycle
PENDING - Detected movie available online
PENDING - Confirmation of patents sale from LLBO to Cyrcadia US
PENDING - New LLBO strategy after sale of patents (+ confirmation that we keep pubic and independent)
PENDING - New LLBO percentage over Cyrcadia
PENDING - LLBO percentage over Circadia Asia, if any
PENDING - Cyrcadia US percentage over Circadia Asia and viceversa
PENDING - Cyrcadia US royalties over Circadia Asia sales and vice versa, if any
PENDING - Confirmation through clinicaltrials.gov of the clinical trial results
PENDING - FDA Class I approval
PENDING - EMA (EU) filling and approval
PENDING - Agreements with hospitals
PENDING - Agreements with health insurance companies
PENDING - Agreements with OTC distributors
PENDING - Confirmation of the iTbra final price in Asia
PENDING - Confirmation of the number of units produced for the initial launch in Asia
PENDING - Communication and advertising campaign in Asia
PENDING - Commercial launch in Asia
PENDING - Confirmation of the iTbra final price in the US
PENDING - Confirmation of the number of units produced for the initial launch in the US
PENDING - Communication and advertising campaign in the US
PENDING - Commercial launch in the US (pilot first)
PENDING - Proof that the iTbra sales are a success after launch, both in Asia and in the US

WHAT WE KNOW

- LLBO stock price has increased 300% over the last three months.
- The iTbra technology started development 30 years ago, but no real product has been sold since then.
- LLBO>Cyrcadia has 3 patents in the US and other pending worldwide.
- Jim Holmes (LLBO CEO) is not in a hurry to communicate to LLBO investors
- The Detected movie is finished but it does not seem to have much media interest
- CISCO promotes Cyrcadia (iTbra) as an example of IoT/AI success but has not done a media campaign yet.
- The clinical trials are not finished but the results so far seems to be OK and in support of a FDA Class I approval.
- The new iTbra drop the wear time from 48 hours to two hours and increase the accuracy from 74.5% to over 87%
- iTbra accuracy is higher than mamograms (87% vs. 83%)
- Cyrcadia US has obtained new financing through Cyrcadia Asia (maybe over $3M)
- Cyrcadia Asia is an independent company (Rob Royea, CEO)
- Cyrcadia Asia will start selling the iTbra + app by the beginning of 2018
- Cyrcadia Asia expects to screen over 3 millions women in one year.
- Cyrcadia Health (US) should start selling in the US by the beginning of 2018 if approved
- Cyrcadia has hired a good advertising agency (Area 23)
- The iTbra has a Class II clearance (tested on 500 patients) that will be used to start selling the services through hospitals by the beginning of 2018.
- The iTbra will be sold later on as a product over-the-counter when receiving FDA Class I approval.
- The iTbra cost/year OTC should be around $200
- The iTbra is an early detection device that does not replace regular mammograms.
- The iTbra main market is young women with dense breast tissue.
- The iTbra cost/use though the hospital should be the same as a mamogram.
- The iTbra will help reduce 500,000 unnecessary biopsies in the US
- Cyrcadia claims to have 500,000 anticipated orders in 2017